STK39 encodes SPAK, a serine/threonine kinase that serves as an effector in the WNK-SPAK/OSR1 signaling cascade regulating ion homeostasis and blood pressure. The protein acts downstream of WNK kinases to phosphorylate ion cotransporters including NKCC1, NKCC2, NCC, and KCC2/KCC3, controlling their activity and modulating sodium reabsorption in the kidney's distal convoluted tubule. STK39 also mediates cell volume regulation in response to hyperosmotic stress 1. Beyond its established role in ion transport, recent evidence identifies STK39 in DNA damage responses: STK39 is phosphorylated by ATM kinase following DNA damage, enabling recruitment to chr2 where it phosphorylates histone H2A.X to amplify homologous recombination repair 2. STK39 is significantly upregulated in pancreatic adenocarcinoma tissues and correlates with PARP inhibitor resistance; combining STK39 inhibition with PARP inhibitors shows synergistic efficacy in suppressing pancreatic cancer growth 2. Additionally, STK39 is highly overexpressed in hepatocellular carcinoma tissues and promotes HCC progression through the PLK1/ERK signaling axis; STK39 depletion attenuates HCC cell growth and metastasis 3. Common STK39 variants are associated with hypertension susceptibility in Europeans and East Asians 4, and species-specific alternative transcripts regulate blood pressure through nephron segment-specific mechanisms 5. These findings position STK39 as a dual regulator of ion homeostasis and cancer-associated signaling pathways with therapeutic potential as a target in pancreatic and hepatocellular malignancies.